WuXi Biologics (Cayman)FRA:1FW2 +1.09%99 EBITDA Margin % is 33.69% as of Dec. 2025, which is 3% below its 10-year median of 34.61. GuruFocus rates FRA:1FW2 with a GF Score™ of 99/100 and a GF Value™ of €4.30 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 944 Biotechnology companies, WuXi Biologics (Cayman) ranks better than 90.36% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
WuXi Biologics (Cayman) EBITDA Margin % Related Terms
WuXi Biologics (Cayman) EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:1FW2 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, WuXi Biologics (Cayman)'s EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WuXi Biologics (Cayman) EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, WuXi Biologics (Cayman)'s EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where WuXi Biologics (Cayman)'s EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WuXi Biologics (Cayman) (FRA:1FW2) has a EBITDA Margin % of 33.69% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on WuXi Biologics (Cayman) and its competitors. This is near median its historical median of 34.61. Over the past decade, WuXi Biologics (Cayman)'s EBITDA Margin % has ranged from 26.37 to 43.87. According to the industry distribution chart, WuXi Biologics (Cayman) ranks #91 out of 944 companies in the Biotechnology industry, placing it in the top 9.6%.
Is WuXi Biologics (Cayman)'s EBITDA Margin % too high?
WuXi Biologics (Cayman)'s current EBITDA Margin % of 33.69% is near median its 10-year median of 34.61. Over the past 10 years, this metric has ranged from a low of 26.37 to a high of 43.87. Based on the distribution chart, WuXi Biologics (Cayman) ranks #91 out of 944 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, WuXi Biologics (Cayman) has a GF Score™ of 99/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does WuXi Biologics (Cayman)'s EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, WuXi Biologics (Cayman) ranks #91 out of 944 companies for EBITDA Margin %. This places WuXi Biologics (Cayman) in the top 10% of its industry — outperforming the majority of peers. Historically, WuXi Biologics (Cayman)'s own EBITDA Margin % has ranged from 26.37 to 43.87 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on WuXi Biologics (Cayman) and its competitors. WuXi Biologics (Cayman)'s current EBITDA Margin % is 33.69%, which is near median its own 10-year median of 34.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi Biologics (Cayman) stock overvalued right now?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) (FRA:1FW2) is currently considered Modestly Undervalued. The stock's GF Value™ is €4.30, compared to a current price of €3.73 — trading 13.4% below its estimated fair value. The current EBITDA Margin % is 33.69%, which is near median its 10-year median of 34.61. WuXi Biologics (Cayman)'s overall GF Score™ is 99/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For WuXi Biologics (Cayman) (FRA:1FW2), the current EBITDA Margin % is 33.69% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is WuXi Biologics (Cayman) (FRA:1FW2) Overvalued in 2026?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) stock appears to be undervalued.
The current stock price of €3.73 is trading 13.4% below its estimated GF Value™ of €4.30.
GuruFocus considers WuXi Biologics (Cayman) to be Modestly Undervalued.
Key valuation signals for FRA:1FW2:
EBITDA Margin %: 33.69% (near median its 10-year median of 34.61)
GF Value™: €4.30 vs. price of €3.73 (13.4% below fair value)
No single metric tells the full story. See the FRA:1FW2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
WuXi Biologics is one of the largest biologics contract development and manufacturing organizations in the world. Incorporated in 2014 following the reorganization of WuXi PharmaTech, WuXi engages in full-lifecycle services beginning from drug discovery, clinical trials, and commercial manufacturing. It focuses on developing refining and manufacturing processes to increase scalability and efficiency for pharmaceutical companies looking to outsource and access specialized knowledge. As of 2024, WuXi derives more than 60% of its revenue from US companies and focuses its operations on high-growth, late-stage, and commercial projects in the biologics sector. WuXi competes with Samsung Biologics, Lonza, and Fujifilm for contracts.
99GF Score
Get the complete analysis for FRA:1FW2
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1FW2 has been successfully added to your 
